Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2024-2028
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2024-2028.)
© 1999 American Heart Association, Inc.
Oral Contraceptives Highlight the Genotype-Specific Association Between Serum Phospholipids and Activated Factor VII
G. Mariani;
J. Conard;
F. Bernardi;
R. Bertina;
V. Vicente Garcia;
H. Prydz;
M. Samama;
P. M. Sandset;
M. Puopolo;
M. V. Ciarla;
R. Poso;
G. D. Di Nucci;
F. Ceci;
G. Marchetti;
for the European Union Concerted Action "Clotart"
From the Hematology and Bone Marrow Transplantation Unit (G.M.),
University Hospital, Palermo; the Department of Human Biopathology (G.D.D.N.,
M.V.C., F.C.), University of Rome "La Sapienza," Rome; and the
Department of Biochemistry and Molecular Biology (F.B., G.M.), University of
Ferrara, Ferrara, Italy; Leiden University Medical Center (R.B.), Leiden, the
Netherlands; the Department of Hematology (V.V.G., R.P), Murcia University
Hospital, Murcia, Spain; the Biotechnology Centre (H.P.), University of Oslo,
Oslo, Norway; Hotel Dieu Hospital (M.S., J.C.), Paris, France; Ulleval
University Hospital (P.M.S.), Oslo, Norway; and the National Health Institute
(M.P.), Rome, Italy.
Correspondence to Prof G. Mariani, Hematology and Bone Marrow Transplantation Unit, Palermo University Hospital, Via del Vespro, 129, 90127 Palermo, Italy. E-mail mariangu{at}tin.it
 |
Abstract
|
|---|
AbstractThe present
analysis was undertaken to study the
effect of oral
contraceptive (OC) use on activated factor VII
(FVIIa) in
subjects characterized by FVII genotypes, with the
further aim
of evaluating the role of lipids in this pharmacological
interaction.
In OC users (n=42) and nonusers (n=130) of comparable
age, we
examined the FVII phenotypic variables (FVII coagulant
activity
[FVIIc], FVII antigen, and FVIIa), FVII genotypes (the
353R/Q
and 5'F7 polymorphisms analyzed in combination; alleles
M1/
M2 and
A1/
A2, respectively), and a number of
lipid and lipoprotein
parameters: serum concentrations of
total cholesterol (chol),
low density lipoprotein and high
density lipoprotein-chol, triglycerides,
phospholipids
(PhLs), apolipoprotein A1, and lipoprotein(a).
PhLs,
triglycerides, apolipoprotein A1, chol, FVII antigen,
FVIIc,
and high density lipoprotein-chol levels were shown to be
statistically
higher in users than nonusers. FVII levels,
particularly those
of FVIIa and FVIIc, were much higher in homozygotes
for the
A1 and
M1 alleles
(
A11 M11), especially in OC users. A
strong
association was found between PhL and FVIIa: in the multiple
regression
analysis, women taking OCs who had elevated PhL
concentrations
also had very high levels of FVIIa, but only if their
genotype
was
A11 M11. These results indicate
that the increased FVII
levels in OC users depend on the FVII
genotype and that high
PhL concentrations predict very high
levels of FVIIa and FVIIc.
Key Words: factor VII activated factor VII phospholipids factor VII genotype
 |
Introduction
|
|---|
Since the introduction of oral contraceptives (OCs) in
the 1960s,
epidemiological studies have revealed an association between
their
use and an increase in the risk of cardiovascular
disease (CVD).
1 2 3 4 5 6 The most important
cardiovascular complications noted
were venous
thromboembolism, myocardial infarction, and thrombotic
stroke,
6 7 8 9 10 11 with higher risk and susceptibility in female
smokers
in the 35+ age range.
12
The increased CVD risk has been attributed to the estrogenic
component7 13 : in fact, it was found to be reduced after
the introduction of OCs containing a lower estrogen
dose,13 14 15 16 17 18 but recently venous thromboembolism was found
to be higher in women using contraceptives containing third-generation
compared with second-generation progestogens.19 20 21 22
The effect of OCs on hemostatis is an increase in the levels of some
coagulation factors (factors II, VII [FVII], IX, X, XI, and VIII; von
Willebrand factor; and fibrinogen), of protein C, and of
protein complexes and fragments related to the activation of
coagulation (thrombin-antithrombin complexes and D-dimer); these
enhance fibrinolysis and decrease the levels of
antithrombin III, protein S, and C4b-binding
protein.23 24 25 26 27 28 29 30 31
Concerning FVII, a relationship between FVII levels, the dose of
estrogen,23 24 25 26 27 28 31 and progestogen (norethisterone but not
D-norgestrel32 ) was
consistently found. It is difficult, though, to pinpoint
whether these changes are due to the estrogen or the progestative
compound, and it is still a matter of debate whether the excess CVD
risk after the use of OCs is related to the resulting
dyslipidemia, the hemostasis changes, or both. Recently, a
meta-analysis33 pointed out the absence of an
association between the duration of OC administration and CVD risk; the
same analysis showed that the increased risk was limited to the
period of OC administration.
Because FVII has attracted attention owing to its association with
lipids (namely triglycerides [TGs] and
cholesterol [chol])34 35 36 37 38 39 40 41 42 43 44 and is considered
a risk factor for CVD,45 47 we thought it appropriate to
analyze, in a group of women on OCs, the interaction between
lipids on the one hand and FVII phenotype and genotype
on the other. In fact, recent data published by our group indicate that
there is a close relationship between FVII, particularly the
activated form (FVIIa), and certain FVII
genotypes,48 49 and that high phospholipid (PhL)
concentrations predict high FVIIa levels.50
 |
Methods
|
|---|
Study Population
Of the 501 volunteer subjects enrolled in the "Clotart"
study
in 5 European countries (France, Italy, the Netherlands, Norway,
and
Spain),
49 50 219 (47.7%) were females; of these, 42
were taking
OCs. All participants declared themselves to be in good
health
and free from CVD, diabetes, and cancer. General enrollment
criteria
were as previously reported.
49 50 Women on OCs
were compared
with a control group of 130 women not taking OCs of
comparable
age range: 21.3 to 50.8 years (median, 32.5) for the women
on
the OC pill and 19.1 to 50.5 years (median, 33.8) for the controls
(in
the tables and in the statistical analysis, data were
adjusted
for age). All the subjects gave their informed
consent.
Blood Sampling
Blood for coagulation studies was taken in 5-mL Vacutainer tubes
(Becton Dickinson Vacutainer Systems Europe) containing 0.5 mL of 0.129
mol/L buffered sodium citrate. For the lipid assays, tubes without
anticoagulant were used; serum was prepared by incubation of blood for
2 hours at 37°C. All samples were centrifuged at
2000g for 15 minutes. Sera and plasma were harvested and
divided into aliquots in plastic tubes (Sorenson BioScience). Samples
were frozen at -80°C in cryotubes and boxes (CryoStore Systems, Nunc
Inc) and subsequently sent on dry ice to the central repository at the
coordinating institution (Thrombosis Center, University of Rome) for
redistribution. For the genetic evaluation, pellets from the citrated
blood samples were harvested in plastic tubes and frozen at -10°C.
Assay Procedures
FVII coagulation activity (FVIIc) and FVII antigen (FVIIAg)
assays were carried out as previously reported.48 49 50 In
detail, FVIIc was assayed by an automated 1-stage assay with a
recombinant thromboplastin preparation with an international
sensitivity index close to 1 (Innovin, Dade). FVIIa was assayed
with a commercial kit (Staclot VIIa-rTF, Diagnostica
Stago).51 48 49 50 Values were expressed in mU/mL, with 30
mU being equivalent to 1 ng of FVIIa. For FVIIa the standard was a
recombinant protein, and for FVIIc and FVIIAg assays, the standard was
a locally prepared, pooled plasma (20 males and 20 females).
Prothrombin fragment 1+2 (F1+2) was assayed with a commercial kit
(Enzygnost F1+2 assay, Dade-Behring).
FVII genetic markers were evaluated as previously
reported.48 49 50 Comparisons were made between the most
frequent FVII genotypes. The alleles of the
polymorphism in the promoter region (5'F7) were denominated
A2 (single decamer insertion) and A1 (absence of
the decamer), and the alleles of the 353 R/Q polymorphism,
characterized by a mutation in the second position of the 353 codon,
were denominated M1 (codon for arginine) and M2
(codon for glutamine). Tight linkage disequilibrium between the
A1 and M1 as well as between the A2
and M2 alleles was found (
values ranging from 0.85
to 0.93), regardless of the population studied.49
Total chol was determined using a commercial kit
(Cholesterol, Du Pont) based on the production of
stoichiometric amounts of
H2O2 generated by
cholesterol esterase and cholesterol
oxidase.52 HDL-chol was determined by using the same
procedure after precipitation of the other
cholesterol-containing lipoprotein fractions by a
phosphotungstate solution buffered to pH 5.753 (HDL-CHOL
Du Pont). LDL-chol was evaluated by the indirect procedure as proposed
by Friedewald et al.54 TGs were assayed by a kinetic
NAD-coupled procedure55 (Triglycerides, Du
Pont). Choline-containing PhLs were evaluated by a choline oxidase
determination of the amount of choline liberated by phospholipase
D56 (Phospholipids, SGM Italia). ApoA1 was determined by a
turbidimetric end-point measurement using 10 mmol/L PEG and a
specific polyclonal antibody57 (APO A1, Du Pont). Lp(a)
was determined by an enzyme immunoassay using a monoclonal
antikringle IV antibody and a polyclonal anti-Lp(a) antibody
conjugated with horseradish peroxidase58 [Macra Lp(a),
Strategic Diagnostic]. Each participating laboratory
carried out 1 or more analyses on the entire study
population.
Statistical Analysis
The procedures used were from the BMDP software
package. The distribution of variables was assessed for deviation
from normality, and the appropriate normalizing (logarithmic)
transformation was used to analyze the data by
parametric methods. Tables were computed on the untransformed
data. Parametric ANOVAs (1-way, 2-way) and ANCOVAs (with age as
a covariate) were used, including the main effects and interactions in
the models. Pearson's linear correlation coefficients were used to
detect any association between variables. A fixed multiple linear
regression model was fitted to the data to estimate the effect (after
adjustment for the effects of age, sex, and country) of high
concentrations in each independent lipid variable on the dependent
one (FVII parameters). Problems due to colinearity were
checked and ruled out during the analysis. The appropriate
Student's t tests were performed to assess the significance
of correlation and regression coefficients and of differences in
coefficients between subgroups.
 |
Results
|
|---|
General Description of the Subject Sample in the "Users" and
"Nonusers" Subgroups
In Table 1

, the levels of the
variables and the statistical
evaluation concerning the data for OC
users and nonusers are
set out. The following variables
were significantly different
between users and nonusers: PhLs,
TGs, ApoA1, chol, FVIIAg,
FVIIc, and HDL-chol.
Influence of FVII Genotypes on FVII Levels in Users
and Nonusers
A highly significant difference in FVII levels was noted between
the genotypes studied and between OC users and nonusers
(Table 2
): women with the A11
M11 genotype had significantly higher values than
did those with other genotypes, more so for FVIIa and FVIIc
than for FVIIAg. OC users had significantly higher levels of FVII than
nonusers. This trend was more apparent with regard to FVIIc and
FVIIAg than to FVIIa. F1+2 levels were significantly higher in the
subjects with the A11 M11 genotype who
were on OCs in comparison with those not taking OCs (1.21 versus 1.10
nmol/L, F=7.4, P=0.008).
Multiple Regression Analysis of the Effect of High Lipid
Concentrations on FVII Levels
High PhL concentrations were associated with very high and
significant FVIIa and FVIIc levels in OC users (Table 3
). The difference between users and
nonusers was more significant for FVIIa and FVIIc than for
FVIIAg. High concentrations of TGs and chol, on the other hand, were
found to be consistently associated with insignificant changes
of FVII in both users and nonusers.
View this table:
[in this window]
[in a new window]
|
Table 3. Multiple Regression Analysis Concerning the
Effect of PhLs, TGs, and Concentrations on FVII Levels as the Dependent
Variable (Age, Sex, and Center Included in the Regression Model)
|
|
Multiple Regression Analysis Regarding the Influence of
FVII Genotypes on the Interaction Between FVII and PhL
In the A11 M11 genotype, high PhL levels were
associated with markedly elevated FVIIa levels in OC users (Table 4
). The differences between users and
nonusers were highly significant. Comparisons with the other
genotypes could not be performed because of the small number of
subjects in this category.
 |
Discussion
|
|---|
This cross-sectional study was carried out using samples taken
from
healthy subjects enrolled through the use of a questionnaire
focusing
on the presence of risk factors for CVD. It is worth
mentioning
that this investigation did not take into account the
details
of OC use, such as the brand of OC and the duration of OC
intake.
If this approach is seen as a bias for comparative evaluations
concerning
the effects of different generations and brands of OC, it
is,
in our opinion, useful in providing a general outline of the
average
impact of OCs on subjects observed in outpatient or inpatient
clinics.
The levels of FVII and the concentrations of lipids in this study are
consistent with those described in other reports of women on
low-dose or sequential OC pills. In fact, the increase noted in FVII
levels represents a well-documented effect of
OCs,14 25 26 27 28 29 30 31 as does that of chol, TGs, HDL-chol, and
apoA1 levels.32 59 60 61 62
Most of the studies14 28 61 62 63 and a recent
review31 have described an increase in FVIIc and FVIIAg
levels that was roughly related to the estrogen dose. In a recent
report,30 FVIIa was also assayed, and it was found to be
increased. In the present study, while analyzing the total
population (Table 1
), we were unable to find a statistically
significant difference between users and nonusers. We noted,
however, great variation in the FVIIa levels, which could explain the
lack of statistical difference between users and nonusers. This
prompted us to evaluate the impact of FVII genotypes, the
importance of which has been demonstrated in determining FVII
levels.48 49 50 The genetic analysis demonstrated
that FVIIc and FVIIa levels were much higher in the A11 M11
genotype than in the others. The use of OCs displayed only an
additional effect on FVII levels, and the presence of an interaction
between OC use and genotype was ruled out (Table 2
).
In a recent report by our group,50 it was observed that
high PhL concentrations were associated with high FVIIa levels. To test
the strength of this association in the context of OC use, we carried
out a multiple regression analysis. This analysis
clearly demonstrated that the major determinants of FVII were PhLs,
whose high concentrations were found to be associated with high levels
of FVIIc, FVIIa, and FVIIAg, mainly in OC users. This was not the case
when high concentrations of TGs and chol were considered in the
analysis as independent variables. The fact that FVIIa and
FVIIc were more affected by high PhL concentrations than high FVIIAg
levels indicates that activation of FVII occurs, together with a
meaningful increase of the total FVII mass. This idea is confirmed by
the presence of significantly higher F1+2 levels in subjects with the
A11 M11 genotype taking OCs compared with those not
on OCs.
For methodological reasons, namely, to use a highly reproducible
and standardized assay method, we have limited our investigation to the
choline-containing PhLs. Other PhLs could also play a role in the
interaction between the various lipid fractions and FVII, but the assay
of the noncholine-containing PhLs (in particular the acidic ones) is
less easily reproducible, and they make up <10% of the whole PhL
concentration, as recently demonstrated by us.50 It must
be emphasized, however, that no conclusive data are available
concerning the respective roles of the different PhL compounds in the
activation of blood coagulation in general and of FVII in
particular.
Because of the possibility of a synergistic effect of the FVII
genotype and PhL in OC users, we evaluated the effect of high
PhL levels in the different FVII genotypic groups and found that the
association between high PhL concentrations and high FVIIa levels was
maximal in OC users with the A11 M11 genotype (Table 4
). These observations would seem to imply that the increase of
FVIIa is likely to occur in most of the women on OCs, because the
A11 M11 genotype is the most frequent (>60% of the
subjects)49 50 and PhLs do increase as a
metabolic effect of the estrogenic
compound.64
In conclusion, this study indicates that PhLs and OCs are important
environmental determinants of FVIIa levels. It is necessary, though, to
ascertain the contribution of their interaction with regard to the
thrombotic risk. Other genetic or environmental factors, alone or in
combination, can further increase the risk in women on OCs and
eventually precipitate the thrombotic event. In fact, recent studies
indicate that there is no evidence that FVII activity, per se, can be
considered a risk factor for thrombotic events in
women.65 66
 |
Acknowledgments
|
|---|
This work was carried out within the framework of the European
Union
Concerted Action BMH1-CT94-1202 "The Role of the FVII-Tissue
Factor
Pathway in Ischemic Heart Disease (Clotart)." The
authors wish
to thank Michael Briggs for his work in amending the
text.
Received August 7, 1998;
accepted January 8, 1999.
 |
References
|
|---|
-
Oral contraceptives and thromboembolism.
[Editorial]. BMJ. 1968;2:187188.
-
Stadel BV. Oral contraceptives and
cardiovascular disease. N Engl J
Med. 1981;305:612618.[Medline]
[Order article via Infotrieve]
-
Stadel BV. Oral contraceptives and
cardiovascular disease. N Engl J
Med. 1981;305:672677.[Medline]
[Order article via Infotrieve]
-
Royal College of General Practitioners.
Oral contraceptive study: further analysis of mortality in oral
contraceptive users. Lancet. 1981;1:541543.[Medline]
[Order article via Infotrieve]
-
Sartwell PE, Stolley PD. Oral contraceptives and
vascular disease. Epidemiol Rev. 1982;4:95109.[Free Full Text]
-
Stolley PD, Strom BL, Sartwell PE. Oral contraceptives
and vascular disease. Epidemiol Rev. 1989;11:241243.[Free Full Text]
-
Inman WHW, Vessey MP, Westerholm B, England A.
Thromboembolic disease and the steroidal content of oral
contraceptives. BMJ. 1970;2:203206.
-
Wiseman RA, McRae KD. Oral contraceptives and the
decline in mortality from circulatory disease. Fertil
Steril. 1981;35:177183.
-
Shapiro S. Oral contraceptives: a time to take stock.
N Engl J Med. 1986;315:450451.[Medline]
[Order article via Infotrieve]
-
Helmrich SP, Rosenberg L, Kaufman DW, Strom BL. Shapiro
S. Venous thromboembolism in relation to oral contraceptive use.
Obstet Gynecol. 1987;69:9195.[Abstract/Free Full Text]
-
Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR,
Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of
venous thromboembolism. Thromb Haemost. 1997;78:327333.
-
Croft P, Hannaford PC. Risk factors for acute
myocardial infarction in women: evidence from the Royal College of
General Practitioner's oral contraception study.
BMJ. 1989;298:165168.
-
Bottinger LE, Boman G, Eklund G, Westerholm G. Oral
contraceptives and thromboembolic disease: effect of lowering oestrogen
content. Lancet. 1980;1:10971101.[Medline]
[Order article via Infotrieve]
-
Meade TW, Greenberg G, Thompson SG. Progestogens
and cardiovascular reactions associated with oral
contraceptives and a comparison of the safety of 50- and 30-µg
oestrogen preparations. BMJ. 1980;280:11571161.
-
Notelovitz M, Kitchens CS, Coone L, McKenzie L, Carter
R. Low-dose oral contraceptive usage and coagulation. Am J
Obstet Gynecol. 1982;142:758761.[Medline]
[Order article via Infotrieve]
-
Kierkegaard A. Deep-vein thrombosis and the oestrogen
content in oral contraception: annual epidemiological analysis.
Contraception. 1985;31:2941.[Medline]
[Order article via Infotrieve]
-
Jespersen J, Petersen KR, Skouby SO. Effects of newer
oral contraceptives on the inhibition of coagulation and
fibrinolysis in relation to dosage and type of steroid.
Am J Obstet Gynecol. 1990;163:396403.[Medline]
[Order article via Infotrieve]
-
Farmer RDT, Preston TD. The risk of venous
thromboembolism associated with low oestrogen oral contraceptives.
J Obstet Gynecol. 1996;15:195200.
-
Jick H, Jick SS, Gurevich V, Myers MW, Vasilakis C.
Risk of idiopathic cardiovascular death and non-fatal
venous thromboembolism in women using contraceptives with different
progestogen components. Lancet. 1995;346:15891593.[Medline]
[Order article via Infotrieve]
-
WHO collaborative study of
cardiovascular disease and steroid hormone
contraception. Effect of different progestogens in low oestrogen oral
contraceptives on venous thromboembolic disease. Lancet. 1995;346:15821588.[Medline]
[Order article via Infotrieve]
-
Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller
HR, Venderbroucke JP. Enhancement by factor V Leiden mutation of
risk of deep-vein thrombosis associated with oral contraceptives
containing a third-generation progestogen. Lancet. 1995;346:15931596.[Medline]
[Order article via Infotrieve]
-
Spitzer WO, Lewis MA, Heineman LAJ, Thorogood M, MacRae
KD. Third generation oral contraceptives and risk of venous
thromboembolic disorders: an international case-control study.
BMJ. 1996;312:8388.[Abstract/Free Full Text]
-
Meade TW, Chakrabarti R, Haines AP, Howarth DJ, North
WRS, Stirling Y. Haemostatic, lipid and blood-pressure profiles of
women on oral contraceptives containing 50 µg or 30 µg
oestrogens. Lancet. 1977;2:948951.[Medline]
[Order article via Infotrieve]
-
Siegbahn A, Ruusuvaara L. Age dependence of blood
fibrinolytic components and the effects of low-dose oral contraceptives
on coagulation and fibrinolysis in teenagers.
Thromb Haemost. 1988;60:361364.[Medline]
[Order article via Infotrieve]
-
Kjaer A, Lebech A-M, Borggaard B, Refn H, Pedersen LR,
Schierup L, Brommelgaard A. Lipid metabolism and
coagulation of two contraceptives: correlation to serum concentrations
of levonorgestrel and gestodene. Contraception. 1989;40:665673.[Medline]
[Order article via Infotrieve]
-
David JL, Gaspard UJ, Gillain D, Raskinet R, Lepot MR.
Hemostatic profile in woman taking low-dose oral contraceptives.
Am J Obstet Gynecol. 1990;163:420423.[Medline]
[Order article via Infotrieve]
-
Daly L, Bonnar J. Comparative studies of 30
µg ethinyl estradiol combined with gestodene and desogestrel on blood
coagulation, fibrinolysis and platelets.
Am J Obstet Gynecol. 1990;163:430437.[Medline]
[Order article via Infotrieve]
-
Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guise L,
Samama M. Changes of haemostatic variables induced by oral
contraceptives containing 50 µg or 30 µg oestrogen: absence of
dose-dependent effect on PAI-1 activity. Thromb Haemost. 1995;74:928932.[Medline]
[Order article via Infotrieve]
-
Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A
comparative study of the effects of the hemostatic system of two
monophasic gestodene oral contraceptives containing 20 µg and 30
µg ethinyl-estradiol. Contraception. 1996;53:7584.[Medline]
[Order article via Infotrieve]
-
Quehenberger P, Loner U, Kapiotis S, Handler S,
Schneider B, Huber J, Speiser W. Increased levels of activated
factor VII and decreased plasma protein S activity and circulating
thrombomodulin during use of oral contraceptives. Thromb
Haemost. 1996;76:729734.[Medline]
[Order article via Infotrieve]
-
Kluft C, Lansink M. Effect of oral contraceptives on
haemostatic variables. Thromb Haemost. 1997;78:315326.[Medline]
[Order article via Infotrieve]
-
Kuhl H, Marz W. Jung-Hoffmann C, Heidt F, Gross W.
Time-dependent alterations in lipid metabolism during
treatment with low-dose oral contraceptives. Am J Obstet
Gynecol. 1990;163:363369.[Medline]
[Order article via Infotrieve]
-
Stampfer MJ, Willet WC, Colditz GA, Speizer FE,
Hennekens CH. Past use of oral contraceptives and
cardiovascular disease: a meta-analysis in the
context of Nurses' Health Study. Am J Obstet Gynecol. 1990;163:285291.[Medline]
[Order article via Infotrieve]
-
Simpson HCR, Mann JL, Meade TW, Chakrabarti R.,
Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability.
Lancet. 1983;2:786790.
-
Scarabin PY, Bara L, Samama M, Pastier D, Orssaud G.
Further evidence that activated factor VII is related to plasma
lipids. Br J Haematol. 1985;61:186187.[Medline]
[Order article via Infotrieve]
-
Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE,
Wilkinson WH, Meade TW. Association between dietary fat increase and
plasma factor VII coagulant activity: a predictor of
cardiovascular mortality.
Atherosclerosis. 1986;60:269277.[Medline]
[Order article via Infotrieve]
-
Bruckert E, Carvalho de Sousa J, Giral P, Soria C,
Chapman MJ, Caen JP, de Gennes JL. Interrelationship of plasma
triglyceride and coagulant factor VII levels in
normotriglyceridemic
hypercholesterolemia.
Atherosclerosis. 1989;75:129134.[Medline]
[Order article via Infotrieve]
-
Carvalho de Sousa J, Soria C, Ayrault-Jarrier M,
Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association
between coagulation factors VII and X with
triglyceride-rich lipoproteins. J Clin
Pathol. 1988;41:940944.[Abstract/Free Full Text]
-
Carvalho de Sousa J, Bruckert E, Giral P, Soria C,
Truffert J, Mirshahi M, de Gennes JL, Caen JP. Coagulation factor VII
and plasma triglycerides. Hemostasis. 1989;19:125130.
-
Miller GJ, Martin JC, Mitropoulos KA, Reeves BE,
Thompson RL, Meade TW, Cooper JA, Cruickshank JK. Plasma factor VII is
activated by postprandial triglyceridemia,
irrespective of dietary fat composition.
Atherosclerosis. 1991;86:163171.[Medline]
[Order article via Infotrieve]
-
Wright D, Poller L, Thomson JM, Gowland E, Burrows GE.
The inter-relationship of factor VII and its activity state with plasma
lipids in healthy male adults. Br J Haematol. 1993;85:348351.[Medline]
[Order article via Infotrieve]
-
Folsom AR, Ma J, Eckfeldt JH, Shahar E, Wu KK. Plasma
phospholipid fatty acid composition and factor VII coagulant activity.
Atherosclerosis. 1994;111:199207.[Medline]
[Order article via Infotrieve]
-
Salomaa V, Rasi V, Pekkanen J, Jauhiainen M, Vahtera E,
Pietinen P, Korhonen H, Kuulasmaa K, Ehnholm C. The effect of saturated
fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic
activity. Atherosclerosis. 1993;103:111.[Medline]
[Order article via Infotrieve]
-
Moor E, Silveira A, van't Hooft F, Suontaka AM,
Eriksson P, Blomback M, Hamsten A. Coagulation factor VII mass and
activity in young men with myocardial infarction at a young age: role
of plasma lipoproteins and factor VII genotype.
Arterioscler Thromb Vasc Biol. 1995;15:655664.[Abstract/Free Full Text]
-
Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti
RR, North RR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Hemostatic
function and ischemic heart disease: principal results of the
Northwick Park Heart Study. Lancet. 1986;2:533537.[Medline]
[Order article via Infotrieve]
-
Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller
GJ. Fibrinolytic activity, clotting factors, long-term incidence of
ischemic heart disease in the Northwick Park Heart Study.
Lancet. 1993;342:10761079.[Medline]
[Order article via Infotrieve]
-
Heinrich J, Balleisen L, Schulte H, Assmann G, Van de
Loo J. Fibrinogen, and FVII in the prediction of coronary risk:
results of the PROCAM Study in healthy men. Arterioscler
Thromb. 1994;14:5459.[Abstract/Free Full Text]
-
Bernardi F, Marchetti G, Arcieri P, Baroncini C,
Papacchini M, Zepponi E, Ursicino N, Chiarotti F., Mariani G. Factor
VII gene polymorphisms contribute about one third of the factor VII
level variation in plasma. Arterioscler Thromb Vasc Biol. 1996;16:7276.
-
Bernardi F, Arcieri P, Bertina RM, Chiarotti F, Corral
M, Pinotti M, Prydz H, Samama M, Sandset PM, Strom R, Vicente Garcia V,
Mariani G. Contribution of FVII genotype to activated
FVII levels: differences in the genotype frequencies between
northern and southern European populations. Arterioscler Thromb
Vasc Biol. 1997;17:25482553.[Abstract/Free Full Text]
-
Mariani G, Bernardi F, Bertina R, Vicente Garcia V,
Prydz H, Samama M, Sandset PM, Di Nucci GD, Testa MG, Bendz B,
Chiarotti F, Ciarla MV, and Strom R. Serum phospholipids are prominent
determinants of factor VII levels in the most common FVII
genotype. Haematologica. In press.
-
Morissey JH, Macik G, Neuenschwander PF, Comp PC.
Quantitation of activated factor VII levels in plasma using a
tissue factor mutant selectively deficient in promoting factor VII
activation. Blood. 1993;81:734744.[Abstract/Free Full Text]
-
Rautel GS, Liedtke RJ. Automatic enzymic measurement of
total cholesterol in serum. Clin Chem. 1978;24:108114.[Abstract/Free Full Text]
-
Grove TH. Effect of reagent pH on determination of
high-density lipoprotein cholesterol by precipitation of
sodium phosphotungstate-magnesium. Clin Chem.. 1979;25:560564.[Abstract/Free Full Text]
-
Friedewald WT, Levy RI, Fredrickson DS. Estimation of
the concentration of low-density lipoprotein cholesterol in
plasma without the use of a preparative ultracentrifuge.
Clin Chem. 1972;8:499502.
-
Stinshoff K, Weisshar D, Staehler F, Hesse D, Gruber W,
Steier E. Relation between concentrations of free glycerol and
triglycerides in human sera. Clin Chem. 1977;23:10291032.[Abstract/Free Full Text]
-
Takayama M, Itoh S, Nagasaki T, Tanimizu I. A new
enzymatic method for the determination of serum choline-containing
phospholipids. Clin Chim Acta. 1977;79:9398.[Medline]
[Order article via Infotrieve]
-
Marcovina S, Curtiss LK, Milne R, Albers JJ.
International Federation of Clinical Chemistry (IFCC) Scientific
Division. Committee on Apolipoproteins, Working group on antibody
reagents, selection and characterization of monoclonal antibodies for
measuring plasma levels of apolipoproteins A-I and B. Ann Biol
Clin. 1990;48:597600.
-
Genest J Jr, Jenner JL, McNamara JR, Ordovas JM,
Silberman SR, Wilson PW, Shaefer EJ. Prevalence of lipoprotein(a)
[Lp(a)] excess in coronary artery disease patients.
Am J Cardiol. 1991;67:10391045.[Medline]
[Order article via Infotrieve]
-
Krauss RM, Roy S, Mishell DR, Casagrande J, Pike MC.
Effect of two low-dose oral contraceptives on serum lipids and
lipoproteins: differential changes in high-density lipoprotein
subclass. Am J Obstet Gynecol. 1983;145:446452.[Medline]
[Order article via Infotrieve]
-
Harvengt C, Desager JP, Gaspard U, Lepot M. Changes in
lipoprotein composition in women receiving two low-dose oral
contraceptives containing ethinylestradiol and gonane progestins.
Contraception. 1988;37:565575.[Medline]
[Order article via Infotrieve]
-
Fotherby K, Calwell ADS. New progestogens in oral
contraception. Contraception. 1994;49:132.[Medline]
[Order article via Infotrieve]
-
Robinson ER. Low-dose combined oral contraceptives.
Br J Obstet Gynecol. 1994;101:10361041.[Medline]
[Order article via Infotrieve]
-
Plu-Bureau G, Scarabin PY, Bara L, Malmejac A, Guize L,
Samama M. Factor VII activation and oral contraceptives. Thromb
Res. 1993;70:275280.[Medline]
[Order article via Infotrieve]
-
Silfverstolpe G, Johnson P, Samsioe G, Svanborg
A, Gustafson A. Effects induced by two different estrogens on serum
individual phospholipids and serum lecithin fatty acid composition.
Horm Metab Res. 1981;13:141145.[Medline]
[Order article via Infotrieve]
-
Folsom AR, Wu KK, Rosamund WD, Sharrett AR, Chambless
LE. Prospective study of hemostatic factors and incidence of
coronary heart disease: the Atherosclerosis
Risk in Communities (ARIC) study. Circulation. 1997;96:11021108.[Abstract/Free Full Text]
-
Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe
GD. Hemostatic factors as predictors of ischaemic heart disease and
stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc
Biol. 1997;17:33213325.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
E.M. Bladbjerg, S.O. Skouby, L.F. Andersen, and J. Jespersen
Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor
Hum. Reprod.,
December 1, 2002;
17(12):
3235 - 3241.
[Abstract]
[Full Text]
[PDF]
|
 |
|